Text Size
116 studies found for:    "Acute promyelocytic leukemia"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Completed Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: lintuzumab;   Drug: arsenic trioxide;   Drug: idarubicin;   Drug: tretinoin
22 Completed Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
Condition: Leukemia
Interventions: Biological: lintuzumab;   Drug: cytarabine;   Drug: idarubicin
23 Recruiting Acute Promyelocytic Leukemia 2006 (APL)
Condition: Leukemia, Promyelocytic, Acute
Interventions: Procedure: Arsenic trioxide;   Procedure: ATRA
24 Unknown † Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: ATRA
25 Recruiting AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Condition: Leukemia, Promyelocytic, Acute
Interventions: Drug: all-trans retinoid acid;   Drug: idarubicin;   Drug: mitoxantrone;   Drug: daunorubicin;   Drug: cytarabine
26 Recruiting S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
27 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
28 Unknown † Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: thioguanine;   Drug: tretinoin;   Procedure: allogeneic bone marrow transplantation;   Procedure: autologous bone marrow transplantation;   Radiation: radiation therapy
29 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
30 Completed Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: tretinoin
31 Active, not recruiting Phase III Trial in Acute Promyelocytic Leukemia Patients
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)
32 Active, not recruiting S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
33 Recruiting Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
Conditions: Acute Promyelocytic Leukemia Female Patients;   Pregnancy
Intervention:
34 Terminated Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Conditions: Acute Myeloid Leukemia (AML);   Acute Promyelocytic Leukemia (APL);   Refractory Anemia With Excess of Blasts (RAEB)
Intervention:
35 Completed Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia;   Leukemia Acute Promyelocytic Leukemia (APL);   Leukemia Acute Lymphoid Leukemia (ALL);   Leukemia Chronic Myelogenous Leukemia (CML);   Leukemia Acute Myeloid Leukemia (AML);   Leukemia Chronic Lymphocytic Leukemia (CLL)
Intervention: Procedure: Allogeneic hematopoietic cell transplantation
36 Completed Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: vorinostat;   Drug: cytarabine;   Drug: etoposide;   Other: pharmacological study;   Other: laboratory biomarker analysis
37 Active, not recruiting Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Promyelocytic Leukemia (M3);   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis
38 Suspended Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: gemtuzumab ozogamicin;   Other: laboratory biomarker analysis
39 Completed Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Conditions: Childhood Acute Promyelocytic Leukemia (M3);   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Relapsing Chronic Myelogenous Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: isotretinoin
40 Completed BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Conditions: Adult Acute Promyelocytic Leukemia (M3);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: BMS-214662;   Other: pharmacological study;   Other: laboratory biomarker analysis
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years